|
Today's Headlines
Antibiotic use during pregnancy may be linked to an increased risk for obesity in the child, according to a study published in the International Journal of Obesity. » More details
|
|
FDA has approved blinatumomab (Blincyto, Amgen) immunotherapy for the treatment of relapsed or refractory Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia. » Read about this breakthrough therapy
|
Continuing Education
This month's CE activity is part of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. From February 2014 through January 2015, pharmacists can earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.
The goal of this month's activity is to educate pharmacists about the prevalence, health consequences, and nonpharmacologic and pharmacologic treatment options for obesity, with a focus on the recommendations made in the 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 14DT12-FKX42.
Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is
https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/
|
|
EDITOR'S PICK
IMPROVE-IT demonstrated, for the first time, that a nonstatin, LDL-C-lowering drug, Zetia (ezetimibe), was able to prevent cardiovascular (CV) events, such as myocardial infarction and stroke, via an incremental reduction in LDL-C when added to statin secondary prevention therapy. » Read more from the American Heart Assocation Scientific Sessions
|
|
|
Like
Tweet
